FCG Investment Co Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

FCG Investment Co grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 40.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 9,465 shares of the biopharmaceutical company’s stock after buying an additional 2,710 shares during the period. FCG Investment Co’s holdings in Gilead Sciences were worth $693,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Tompkins Financial Corp boosted its holdings in Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the period. Fortitude Family Office LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $29,000. Private Wealth Management Group LLC bought a new stake in Gilead Sciences during the fourth quarter valued at about $29,000. Sachetta LLC purchased a new position in shares of Gilead Sciences in the 4th quarter worth approximately $30,000. Finally, Rakuten Securities Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth $33,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

NASDAQ:GILD traded down $1.81 during mid-day trading on Thursday, hitting $66.59. The company’s stock had a trading volume of 3,995,673 shares, compared to its average volume of 8,998,495. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $82.96 billion, a price-to-earnings ratio of 184.97, a P/E/G ratio of 2.91 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The stock has a fifty day moving average of $66.03 and a 200-day moving average of $72.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same quarter in the prior year, the business earned $1.37 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.63%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s dividend payout ratio is 855.56%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Morgan Stanley cut their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Royal Bank of Canada restated a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a research report on Monday. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. Finally, TD Cowen lowered their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Twelve equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $83.47.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.